Dabrafenib-trametinib

ROAR, NCI-MATCH (subprotocol H)

Dabrafenib-trametinib ROAR, NCI-MATCH (subprotocol H)

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

ORR

ADJUSTMENTS

Quality of life

Serious and disabling adverse effects

Other adjustments

Dabrafenib-trametinib ROAR, NCI-MATCH (subprotocol H)

FINAL SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

3

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: dMMR/MSI-H solid tumour
Therapeutic Indication: Adult and paediatric patients ≥1 year of age with unresectable or metastatic solid tumours with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options
Experimental Arm: Dabrafenib-trametinib
Control Arm: Single arm